Alyeska Investment Group L.P. Acquires New Stake in Maze Therapeutics, Inc. $MAZE

Key Points

• Alyeska Investment Group L.P. has acquired a new stake in Maze Therapeutics, Inc., purchasing 125,000 shares valued at approximately $1.38 million. This represents about 0.29% of the company's total shares as of the latest reporting period.
• Maze Therapeutics has seen a range in its stock price, with a 52-week low of $6.71 and a high of $19.19, currently opening at $15.88.
• Equities analysts have mixed views on Maze Therapeutics, with ratings ranging from "sell" to "buy", including a price target of up to $34.00 from HC Wainwright.

Alyeska Investment Group L.P. purchased a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 125,000 shares of the company's stock, valued at approximately $1,376,000. Alyeska Investment Group L.P. owned 0.29% of Maze Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of MAZE. Frazier Life Sciences Management L.P. bought a new position in shares of Maze Therapeutics during the first quarter valued at about $45,460,000. Hhlr Advisors LTD. purchased a new position in Maze Therapeutics during the 1st quarter valued at about $5,037,000. Ghisallo Capital Management LLC bought a new position in Maze Therapeutics during the 1st quarter valued at approximately $330,000. Driehaus Capital Management LLC purchased a new stake in Maze Therapeutics in the 1st quarter worth approximately $1,455,000. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $2,752,000.

Wall Street Analysts Forecast Growth

MAZE has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. BTIG Research started coverage on shares of Maze Therapeutics in a research report on Tuesday, September 2nd. They set a "buy" rating and a $30.00 price objective on the stock. HC Wainwright initiated coverage on shares of Maze Therapeutics in a report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 price objective for the company. Finally, Wedbush started coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat, Maze Therapeutics presently has an average rating of "Buy" and a consensus price target of $26.33.

Maze Therapeutics Price Performance

MAZE traded up $8.78 during trading on Thursday, reaching $24.80. The stock had a trading volume of 5,074,476 shares, compared to its average volume of 348,962. The stock's 50 day moving average is $15.04 and its two-hundred day moving average is $12.19. Maze Therapeutics, Inc. has a one year low of $6.71 and a one year high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.